A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, non-randomized, dose-escalation phase 1 trial to evaluate
the safety and tolerability of SHR3162 in participants with advanced solid tumors.